WATERTOWN, Mass. --(BUSINESS WIRE)--May 8, 2020-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat

WATERTOWN, Mass. --(BUSINESS WIRE)--May 5, 2020-- Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced the closing of its initial public offering of 4,025,000 shares of common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their

WATERTOWN, Mass. --(BUSINESS WIRE)--Apr. 30, 2020-- Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced the pricing of its initial public offering of 3,500,000 shares of common stock at a public offering price of $16.00 per share, before deducting underwriting discounts and commissions.

Proceeds to advance company’s lead product candidates for the treatment of chronic rhinosinusitis Watertown, MA  – January 29, 2020 – Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for

LYRA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR A PHASE 2 CLINICAL TRIAL OF LYR-210 FOR CHRONIC RHINOSINUSITIS Lyra to incorporate U.S. clinical sites into its ongoing global LANTERN trial, a Phase 2 clinical study of LYR‑210 LYR-210 designed to provide up to